Payer Coverage Considerations for New Treatments for Alzheimer Disease

Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home and vehicle modifications to enhance quality of life.

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).

African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.